Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study
David T Yeung(Royal Adelaide Hospital), On Behalf of the ALLG(Australasian Leukaemia and Lymphoma Group), Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Naranie Shanmuganathan(South Australia Pathology), Kate Burbury(The University of Melbourne), Carolyn Grove(The University of Western Australia), David M. Ross(Flinders Medical Centre), Cecily Forsyth(Gosford Hospital), Timothy P. Hughes(Royal Adelaide Hospital), John Reynolds(The Alfred Hospital), Jake Shortt(The University of Melbourne), Lynette Chee(The Royal Melbourne Hospital), Steven Lane(QIMR Berghofer Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Andrew Grigg(The Royal Melbourne Hospital), Mannu Walia(St Vincents Institute of Medical Research), Ilona Cunningham(The University of Sydney), Nick Viiala(Liverpool Hospital), Peter Browett(University of Auckland), Matthew P.F. Wright(Fiona Stanley Hospital), Robin Filshie(St Vincent's Hospital Melbourne), Alwyn Bernard D'Souza(Wellington Hospital)
Cited by 5
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464